- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03289455
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)
A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity Of AUTO3, a CAR T Cell Treatment Targeting CD19 And CD22 in Paediatric And Young Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- University College London Hospitals NHS Foundation Trust
-
London, United Kingdom
- Great Ormond Street Hospital For Children NHS Foundation Trust
-
Manchester, United Kingdom
- Royal Manchester Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
Male or female patients aged 1-24 years with high risk (HR) relapsed/refractory B-lineage ALL, AND:
- Any bone marrow (BM) relapse or central nervous system (CNS) relapse with detectable BM disease after allogeneic stem cell transplant (SCT) and must be ≥6 months from SCT at the time of AUTO3 infusion; OR,
- HR first relapse; OR,
- Standard risk relapse patients with HR cytogenetics; OR,
- Second or greater relapse; OR,
- BM minimal residual disease (MRD) ≥10-³ prior to planned SCT; OR,
Any on-treatment relapse in patients aged 16-24 years.
(Phase II Only - Criteria in addition to those described above:)
- Primary refractory disease; OR,
- Patients with Philadelphia chromosome positive ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor (TKI) therapy, or if TKI therapy is contraindicated; OR,
- Isolated CNS relapse but with ≤CNS Grade 2 disease at time of enrolment.
- Documentation of CD19 and or CD22 expression on leukaemic blasts in the BM, peripheral blood, or cerebrospinal fluid within 3 months of screening.
- Detectable disease in the BM at a level ≥10-⁴ (Phase I only).
- Absolute lymphocyte count ≥0.5 x 10⁹/L.
- Adequate renal, hepatic, pulmonary, and cardiac function.
- Karnofsky (age ≥10 years) or Lansky (age <10 years) score ≥50%.
- Willing and able to give written, informed consent to the current study (patient and/or parent or legal guardian).
Exclusion Criteria:
- Isolated extra-medullary disease relapse.
- Active CNS involvement of ALL (CNS Grade 3 per National Comprehensive Cancer Network guidelines).
- Active infectious bacterial or viral disease requiring IV anti-microbials for treatment.
- Females who are pregnant or lactating.
- Females of child-bearing potential and post pubertal male participants who are unwilling to use highly effective methods of contraception for a period of 1 year after the AUTO3 infusion.
- Inability to tolerate leukapheresis.
- Prior CD19 or CD22 targeted therapy with Grade 4 toxicity or ≥refractory Grade 3 cytokine release syndrome (CRS) or ≥Grade 3 drug related CNS toxicity.
- Pre-existing significant neurological disorder.
- Stem Cell Transplant patients only: active significant acute graft versus host disease (GVHD) or moderate/severe chronic GVHD requiring systemic steroids or other immunosuppressant within 4 weeks of enrolment.
The following medications are excluded:
- Steroids: Therapeutic doses of steroids must be stopped >72 hours prior to AUTO3 infusion and leukapheresis. However, physiological replacement doses of steroids are allowed: <12 mg/m2/day hydrocortisone or equivalent.
- Allogeneic cellular therapy: Any donor lymphocyte infusions must be completed >6 weeks prior to AUTO3 infusion.
- Graft versus host disease therapies: Any drug used for GVHD must be stopped >4 weeks prior to AUTO3 infusion.
- Chemotherapy: Should be stopped 1 week prior to leukapheresis and 2 days prior to starting pre-conditioning chemotherapy.
- Known allergy to albumin, dimethyl sulfoxide, cyclophosphamide or fludarabine.
For AUTO3 Infusion: Patients meeting any of the following exclusion criteria will not be treated with AUTO3 or treatment will be delayed until they no longer meet these criteria:
- Severe intercurrent infection.
- Requirement for supplementary oxygen.
- Allogeneic transplant recipients with active significant acute GVHD overall Grade ≥II or moderate/severe chronic GVHD requiring systemic steroids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AUTO3
Paediatric patients with relapse or refractory B-cell ALL
|
Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Grade 3-5 Toxicities Occurring Within the Dose Limiting Toxicity (DLT) Period of AUTO3 Infusion
Time Frame: Within 30 days (+/- 3 days) after the last dose of AUTO3.
|
Within 30 days (+/- 3 days) after the last dose of AUTO3.
|
|
Number of Patients With Dose Limiting Toxicity (DLT) of AUTO3
Time Frame: Within 30 days (+/- 3 days) after the last dose of AUTO3.
|
DLT was defined as i) any new non-hematological adverse event (AE) of Grade 3 or higher toxicity using the NCI CTCAE (version 5.0), which was probably or definitely related to AUTO3 therapy, which occurred within the DLT evaluation period, and which failed to resolve to Grade 2 or better within 14 days, despite appropriate supportive measures; ii) Grade 4 cytokine release syndrome (CRS) or neurotoxicity, cerebral edema, or Grade 3 neurotoxicity (including cerebral edema) that lasted >72 hours; iii) Grade >3 disseminated intravascular coagulation; iv) Grade >2 infusion reaction; v) Any other fatal event (Grade 5) or life-threatening event (Grade 4) that could not be managed with conventional supportive measures or which in the opinion of the Safety Evaluation Committee (SEC) necessitated dose reduction or other modification to trial treatment to avoid a similar hazard in future patients.
|
Within 30 days (+/- 3 days) after the last dose of AUTO3.
|
Number of Patients Achieving Morphological Remission (Complete Response(CR) or Complete Response With Incomplete Count Recovery (CRi) and Minimal Residual Disease (MRD)-Negative Response in the Bone Marrow (PCR)).
Time Frame: Within 30 days (+/- 3 days) post AUTO3 infusion
|
Morphological response evaluations were based on the response criteria for ALL according to the NCCN guidelines version 2.2014.
Minimal residual disease-negative status was achieved if MRD was <10^-4 (0.01%) by PCR amplification of individual rearrangements of Ig genes and/or flow cytometry MRD testing.
|
Within 30 days (+/- 3 days) post AUTO3 infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of Generating AUTO3: Number of Patients' Cells Successfully Manufactured as a Proportion of the Number of Patients Undergoing Leukapheresis
Time Frame: Up to 8 weeks post leukapheresis
|
Feasibility of product generation was examined by assessing the number of AUTO3 successfully manufactured as a fraction of the number of patients undergoing leukapheresis (all patients screened).
|
Up to 8 weeks post leukapheresis
|
Event-Free Survival (EFS) by Morphological Analysis
Time Frame: Up to 2 years
|
Time from date of first AUTO3 infusion until the earliest of treatment failure (defined as not achieving CR/CRi post AUTO3 infusion / no response), morphological relapse, or death due to any cause, whichever occurred first.
|
Up to 2 years
|
Number of Patients With CD19- and/or CD22-negative Relapse
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Relapse-Free Survival (RFS) by Morphological Analysis
Time Frame: Up to 2 years
|
Time from first achievement of morphological CR/CRi post AUTO3 treatment until the earliest of morphological relapse, or death due to any cause, whichever occurred first.
|
Up to 2 years
|
Overall Survival (OS)
Time Frame: Up to 2 years after the last patient was infused
|
Calculated from the date of AUTO3 treatment to the date of death anytime post AUTO3 infusion.
Patients who had not died were censored at the date of last contact.
|
Up to 2 years after the last patient was infused
|
Expansion of AUTO3 Following Adoptive Transfer
Time Frame: Up to 2 years
|
Expansion of AUTO3 was measured as the median peak (Cmax) of transgene levels in the peripheral blood after AUTO3 infusion
|
Up to 2 years
|
Persistence of AUTO3 Following Adoptive Transfer
Time Frame: Up to 2 years
|
Persistence of AUTO3 was measured by quantitative polymerase chain reaction (qPCR) and/or flow cytometry at a range of time points in the peripheral blood and the bone marrow. Persistence was defined as the timepoint in days of last detectable CAR T cell by qPCR or last assessment if zero copies per μg DNA (whichever occurred later) before morphological relapse (Tlast). |
Up to 2 years
|
Duration of B Cell Aplasia
Time Frame: Up to 2 years
|
Depletion of circulating B cells assessed by flow cytometry at a range of time points in the peripheral blood
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUTO3-PA1
- 2016-004680-39 (EUDRACT_NUMBER)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Childhood Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)CompletedRecurrent Adult Lymphoblastic Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
National Cancer Institute (NCI)Children's Cancer GroupCompletedRecurrent Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Lymphoblastic LymphomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedAdult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid LeukemiaSwitzerland
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingPreviously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic... and other conditionsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedSecondary Acute Myeloid Leukemia | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Promyelocytic Leukemia (M3) | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid LeukemiaUnited States
Clinical Trials on AUTO3 (CD19/22 CAR T cells
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingNon-hodgkin's LymphomaChina
-
Chinese PLA General HospitalUnknown
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNon-hodgkin Lymphoma,B CellChina
-
Chinese PLA General HospitalUnknownRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditionsChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAcute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B CellChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Miltenyi Biomedicine GmbHRecruitingB-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia RefractoryGermany
-
Shenzhen Geno-Immune Medical InstituteRecruiting
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom